Science & evidence
Peptide science, graded honestly.
Petides™ trademark exists because veterinary peptide research runs roughly 5–10 years behind human medicine — and it's accelerating. Our job is to bring it to your practice responsibly, the moment the evidence supports it.
Plain language
What is a peptide, really?
A peptide is a short chain of amino acids — long enough to act like a small protein, short enough to be made precisely in a lab. Your patient already runs on dozens of them: insulin, glucagon, GnRH, vasopressin, all of the body's own messengers.
Modern peptide therapeutics either replace those messengers, mimic them more selectively, or borrow biological signals (wound healing, immune modulation, satiety) from elsewhere in the body and deliver them on purpose.
The science is moving fast — and it's where a lot of next-decade veterinary medicine will come from. That's why we built Petides™ trademark the way we did: honest tiers, real citations, and dosing built with veterinary advisors, not borrowed from forums.
The grading rubric
Three tiers. One promise: we tell you which one you're looking at.
Standard-of-care
Peptides already routine in veterinary practice — supported by established clinical use and/or regulatory approval.
Bar of evidence
Approved labels or unambiguous standard-of-care position in textbooks and guidelines.
Examples
Insulin · Desmopressin · Glucagon · GnRH analogs · NT-proBNP (diagnostic)
In clinical trials
Active, registered clinical investigation in the relevant species. Promising — but not yet established or approved.
Bar of evidence
Listed on a public registry (e.g., ClinicalTrials.gov, VeterinaryClinicalTrials.org) with a defined protocol.
Examples
OKV-119 (MEOW-1, cats) · Antimicrobial peptides · Companion-animal energy-balance peptides
Investigational / veterinary discretion
Biological rationale and preclinical or uncontrolled clinical signals exist — but controlled species-specific trials are limited or absent.
Bar of evidence
Mechanistic basis + published preclinical or uncontrolled clinical use; informed-consent discussion required.
Examples
BPC-157 (rodent-model evidence) · TB-500 / Tβ4 fragment · SS-31 · Thymosin α-1
Mechanism explainers
The biology — set in mono where it counts.
Actin & cell-migration
Tβ4-family peptides sequester G-actin and accelerate keratinocyte/endothelial migration — the molecular basis for wound and tendon healing models.
Ac-LKKTETQ · Tβ4(17–23)
GLP-1 receptor pathway
GLP-1R agonism slows gastric emptying, increases satiety via hypothalamic pathways, and enhances glucose-dependent insulin secretion. The biology behind the MEOW-1 trial.
GLP-1R · GPCR · Gs-coupled
Antimicrobial mechanism
Cationic, amphipathic peptides bind anionic microbial membranes and disrupt them — a targeted alternative to broad-spectrum antibiotics in the AMR era.
Cationic · amphipathic · membrane-active
Our process
How we vet a peptide before we sell it.
A peptide doesn't earn a place in our library because it's trendy. It earns it because, at every step below, it survives a yes/no from a veterinarian on our advisory board.
- 1Source — manufacturer audit and chain-of-custody documentation.
- 2Synthesize — SPPS or recombinant, with batch records retained.
- 3Assay — independent HPLC + mass-spec on every lot.
- 4Review — veterinary scientific advisory board signs off on label tier.
- 5Label — published with evidence tier, citations, and contraindications.